Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.
Ilya G SerebriiskiiValery PavlovRossella TricaricoGrigorii AndrianovEmmanuelle NicolasMitchell I ParkerJustin NewbergGarrett M FramptonJoshua E MeyerErica A GolemisPublished in: Nature communications (2022)
Loss of expression or activity of the tumor suppressor PTEN acts similarly to an activating mutation in the oncogene PIK3CA in elevating intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), inducing signaling by AKT and other pro-tumorigenic signaling proteins. Here, we analyze sequence data for 34,129 colorectal cancer (CRC) patients, capturing 3,434 PTEN mutations. We identify specific patterns of PTEN mutation associated with microsatellite stability/instability (MSS/MSI), tumor mutational burden (TMB), patient age, and tumor location. Within groups separated by MSS/MSI status, this identifies distinct profiles of nucleotide hotspots, and suggests differing profiles of protein-damaging effects of mutations. Moreover, discrete categories of PTEN mutations display non-identical patterns of co-occurrence with mutations in other genes important in CRC pathogenesis, including KRAS, APC, TP53, and PIK3CA. These data provide context for clinical targeting of proteins upstream and downstream of PTEN in distinct CRC cohorts.
Keyphrases
- cell proliferation
- pi k akt
- signaling pathway
- end stage renal disease
- genome wide
- electronic health record
- chronic kidney disease
- ejection fraction
- newly diagnosed
- big data
- peritoneal dialysis
- protein kinase
- binding protein
- dna methylation
- anti inflammatory
- long non coding rna
- young adults
- drug delivery
- small molecule
- protein protein